Metformin: New Preparations and Nonglycemic Benefits

@article{Fujita2017MetforminNP,
  title={Metformin: New Preparations and Nonglycemic Benefits},
  author={Yoshihito Fujita and Nobuya Inagaki},
  journal={Current Diabetes Reports},
  year={2017},
  volume={17},
  pages={1-10}
}
Metformin has been widely used for over 5 decades. New preparations have been developed for possible enhancement of efficiency, tolerability, and pleiotropic nonglycemic effects. Extended-release metformin has contributed to adherence and improved gastrointestinal tolerability. Delayed-release metformin acts in the lower gastrointestinal tract and exerts glucose-lowering effects at lower plasma metformin levels, which might suggest use of this biguanide in patients with chronic kidney disease… Expand
Metformin turns 62 in Pharmacotherapy: emergence of non-glycaemic effects and potential novel Therapeutic applications.
TLDR
Anti-inflammatory and antioxidant effects of metformin seem to qualify it as an adjunct therapy in treating infectious diseases such as tuberculosis, viral hepatitis, and the current novel Covid-19 infections. Expand
Metformin: clinical use in type 2 diabetes
TLDR
With no long-term studies comparing it against newer glucose-lowering drugs, some of which have more robust evidence for cardioprotection, metformin’s established role as ‘foundation therapy’ in type 2 diabetes may justifiably be challenged. Expand
Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Despite its position as the first-line drug for treatment of type 2 diabetes mellitus, the mechanisms underlying the plasma glucose level-lowering effects of metformin (1,1-dimethylbiguanide) stillExpand
Optimizing diabetes treatment in the presence of obesity
TLDR
The authors review medications approved for the treatment of type 2 diabetes mellitus that also have weight loss as a side effect and discuss glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, neuroendocrine peptide hormones, alpha-glUCosidase inhibitors, and metformin. Expand
Metformin inhibits the activation of melanocortin receptors 2 and 3 in vitro: A possible mechanism for its anti-androgenic and weight balancing effects in vivo?
TLDR
This study investigates its specific effect through the melanocortin receptor 2 (MC2R) on signaling targeting adrenal steroidogenesis and shows that metformin acts on MC2R and MC3R signaling directly. Expand
Anti-diabetic effects of natural products an overview of therapeutic strategies
TLDR
It is suggested that medicinal plants can be used to treat diabetic mellitus through hormonal regulation and metabolic regulation as a therapeutic medication. Expand
Metformin, lipids and atherosclerosis prevention
TLDR
An overview of recent publications that extend clinically relevant knowledge relating to metformin's effects on lipids and atherosclerotic vascular disease and/or provide insights into the drug's mechanisms of action on the heart and vasculature is provided. Expand
Metformin Used for Weight Loss by Non-Diabetic Sudanese Females
TLDR
It is concluded that women who used Metformin over the counter had a good experience with it especially when combined with diet and exercise. Expand
Clinical efficacy of metformin combined with lifestyle intervention for treatment of childhood obesity with hyperinsulinemia
Objective: The aim of the current study was to investigate the clinical effects of metformin combined with lifestyle intervention on childhood obesity with hyperinsulinemia. Methods: Obese childrenExpand
Metformin extended-release versus metformin immediate-release for adults with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
AIM To compare the efficacy and tolerability metformin extended-release (MXR) and the conventional metformin immediate-release (MIR) in adults with type 2 diabetes mellitus (T2DM) METHODS: PubMed,Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 121 REFERENCES
METFORMIN: NONGLYCEMIC EFFECTS AND POTENTIAL NOVEL INDICATIONS.
  • A. Anabtawi, J. Miles
  • Medicine
  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2016
TLDR
Evidence that metformin is safe in patients with HF and associated with a reduction in newly incident HF and in HF mortality is found; there is evidence that individuals with CKD-3, who are at increased cardiovascular risk, stand to benefit from meetformin therapy. Expand
Metformin: an old but still the best treatment for type 2 diabetes
TLDR
The role of metformin in the treatment of patients with type 2 diabetes is reviewed, its potential role for a variety of insulin resistant and pre-diabetic states, obesity, metabolic abnormalities associated with HIV disease, gestational diabetes, cancer, and neuroprotection are discussed. Expand
The “slower” the better
TLDR
Metformin is primarily used to treat type 2 diabetes, but it is also beneficial in the treatment of other metabolic diseases such as the polycystic ovarian syndrome (PCOS) and the non alcoholic fat liver disease (NAFLD). Expand
Metformin and the gastrointestinal tract
TLDR
It is believed that metformin response and tolerance is intrinsically linked with the gut, and how this can affect the efficacy of meetformin treatment in the individual, and contribute to the side effects associated with met formin intolerance. Expand
Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus
TLDR
It is found that metformin withdrawal was associated with a reduction of active and total GLP-1 and elevation of serum bile acids, especially cholic acid and its conjugates, which reversed when meetformin was restarted. Expand
Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus
TLDR
Patients switched to extended release metformin XR derived the same clinical and metabolic benefits as for standard metform in hospital based outpatients with type 2 diabetes mellitus but with reduced dosage, fewer gastrointestinal side effects and a greater sense of well being and satisfaction on medication. Expand
Metformin improves healthspan and lifespan in mice
TLDR
It is shown that long-term treatment with metformin starting at middle age extends healthspan and lifespan in male mice, while a higher dose (1% w/w) was toxic. Expand
Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study
TLDR
In this retrospective chart review, patients switched from immediate-release metformin to met formin-XR experienced fewer GI side effects on comparable doses of the extended-release meetformin. Expand
Repurposing metformin for cancer treatment: current clinical studies
TLDR
The role of metformin as a potential cancer treatment is reviewed to critically review the results of a small number of completed trials. Expand
Metformin in women with PCOS, Pros
TLDR
Although this drug should not be used as a first-line treatment for ovulatory dysfunctions in adult women with PCOS, there are data supporting the suggestion that in many cases pretreatment with metformin may favor ovulatory response to clomiphene citrate. Expand
...
1
2
3
4
5
...